242 related articles for article (PubMed ID: 22905983)
1. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism.
Buyue Y; Misenheimer TM; Sheehan JP
J Thromb Haemost; 2012 Oct; 10(10):2086-98. PubMed ID: 22905983
[TBL] [Abstract][Full Text] [Related]
2. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
Westmark PR; Tanratana P; Sheehan JP
J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: a rebuttal.
Hemker HC; Béguin S
J Thromb Haemost; 2013 Mar; 11(3):564. PubMed ID: 23289967
[No Abstract] [Full Text] [Related]
4. Low-molecular-weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: a reply to rebuttal.
Buyue Y; Misenheimer TM; Sheehan JP
J Thromb Haemost; 2013 Mar; 11(3):565-6. PubMed ID: 23332108
[No Abstract] [Full Text] [Related]
5. Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite.
Buyue Y; Sheehan JP
Blood; 2009 Oct; 114(14):3092-100. PubMed ID: 19414859
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan.
Mauray S; de Raucourt E; Talbot JC; Dachary-Prigent J; Jozefowicz M; Fischer AM
Biochim Biophys Acta; 1998 Sep; 1387(1-2):184-94. PubMed ID: 9748565
[TBL] [Abstract][Full Text] [Related]
7. The regulation of factor IXa by supersulfated low molecular weight heparin.
Misenheimer TM; Sheehan JP
Biochemistry; 2010 Nov; 49(46):9997-10005. PubMed ID: 20945941
[TBL] [Abstract][Full Text] [Related]
8. The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin.
Yuan QP; Walke EN; Sheehan JP
Biochemistry; 2005 Mar; 44(9):3615-25. PubMed ID: 15736971
[TBL] [Abstract][Full Text] [Related]
9. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.
Wood JP; Baumann Kreuziger LM; Desai UR; Mast AE
Br J Haematol; 2016 Oct; 175(1):123-32. PubMed ID: 27301751
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
11. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
[TBL] [Abstract][Full Text] [Related]
12. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
Chan AK; Berry LR; Monagle PT; Andrew M
Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
[TBL] [Abstract][Full Text] [Related]
13. Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa.
Sheehan JP; Kobbervig CE; Kirkpatrick HM
Biochemistry; 2003 Sep; 42(38):11316-25. PubMed ID: 14503882
[TBL] [Abstract][Full Text] [Related]
14. Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase.
Anderson JA; Fredenburgh JC; Stafford AR; Guo YS; Hirsh J; Ghazarossian V; Weitz JI
J Biol Chem; 2001 Mar; 276(13):9755-61. PubMed ID: 11134031
[TBL] [Abstract][Full Text] [Related]
15. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.
Schick BP; Maslow D; Moshinski A; San Antonio JD
Blood; 2004 Feb; 103(4):1356-63. PubMed ID: 14576044
[TBL] [Abstract][Full Text] [Related]
16. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Garcia DA; Baglin TP; Weitz JI; Samama MM
Chest; 2012 Feb; 141(2 Suppl):e24S-e43S. PubMed ID: 22315264
[TBL] [Abstract][Full Text] [Related]
17. Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism.
Sheehan JP; Walke EN
Blood; 2006 May; 107(10):3876-82. PubMed ID: 16672689
[TBL] [Abstract][Full Text] [Related]
18. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
[TBL] [Abstract][Full Text] [Related]
19. Residues Tyr253 and Glu255 in strand 3 of beta-sheet C of antithrombin are key determinants of an exosite made accessible by heparin activation to promote rapid inhibition of factors Xa and IXa.
Izaguirre G; Olson ST
J Biol Chem; 2006 May; 281(19):13424-13432. PubMed ID: 16517611
[TBL] [Abstract][Full Text] [Related]
20. Coagulation inhibition capacities of low-molecular mass and unfractionated heparin, as determined by thrombin generation.
Elgue G; Sanchez J; Egberg N; Olsson P
Thromb Res; 1994 Sep; 75(5):539-49. PubMed ID: 7992254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
